BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Rapport
Temps Différé Nasdaq Stockholm  -  13/05 17:29:47
30.55 SEK   +1.50%
28/04Biovica complète la soumission 510(k) du DiviTum®TKa à la FDA
CI
15/03Biovica International AB (publ) annonce ses résultats financiers pour le troisième trimestre et les neuf mois terminés le 31 janvier 2022
CI
15/03Biovica International AB (Publ) fournit des prévisions de bénéfices pour l'année complète 2022
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur BIOVICA INTERNATIONAL AB (PUBL)
09/05Biovica's DiviTum®TKa at ASCO
28/04Biovica completes 510(k) submission for DiviTum®TKa to the FDA
28/04Biovica completes 510(k) submission for DiviTum®TKa to the FDA
28/04Biovica Capital Markets Day invitation May 17, 2022
22/03Positive DiviTum®TKa results published in npj Breast Cancer
15/03TRANSCRIPT : Biovica International AB, Q3 2022 Earnings Call, Mar 15, 2022
15/03Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months..
15/03Biovica International AB Provides Earnings Guidance for the Full Year 2022
14/03Biovica establishes US CLIA lab to further strengthen DiviTum®TKa launch
14/03Biovica Establishes US CLIA Lab to Further Strengthen DiviTumTKa Launch
18/02Nomination Committee for Biovica for the 2022 Annual General Meeting
18/02Biovica International AB Announces Nomination Committee Appointments
14/02DiviTum®TKa results from PYTHIA published in EJC
14/02Biovica Announces Positive DiviTum®TKa Results from the European Multicenter Study PYTH..
07/02Biovica provides time-plan for FDA submission
2021TRANSCRIPT : Biovica International AB, Q2 2022 Earnings Call, Dec 01, 2021
2021Biovica International
2021Q2 Interim report - Promising results published at ESMO
2021Biovica International AB Provides Earnings Guidance for the Full Year 2021
2021Biovica International AB Reports Earnings Results for the Second Quarter and Six Months..
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
2021Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
2021Biovica International
2021Biovica's DiviTum®TKa in three studies at SABCS 2021
2021Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
2021Biovica International
2021Biovica's DiviTum®TKa results published in Journal of Medical Economics
2021BIOVICA INTERNATIONA : Biovica International
2021BIOVICA INTERNATIONAL : Announcement from Biovica International's extra general meeting
2021BIOVICA INTERNATIONAL : Notice of extra general meeting in Biovica International AB
2021BIOVICA INTERNATIONAL AB(OM : BIOVIC B) added to S&P Global BMI Index
2021BIOVICA INTERNATIONAL : DiviTum®TKa results from SWOG study published in Clinical Cancer R..
2021Biovica Announces DiviTum®TKa results from SWOG study published in Clinical Cancer Rese..
2021BIOVICA INTERNATIONAL : Promising DiviTumTKa results from BioItaLEE study presented at ESM..
2021BIOVICA INTERNATIONA : Biovica International
2021BIOVICA INTERNATIONAL : provides update on FDA application process
2021Biovica International AB Provides Update on FDA Application Process
2021TRANSCRIPT : Biovica International AB, Q1 2022 Earnings Call, Sep 02, 2021
2021BIOVICA INTERNATIONAL : Announcement from Biovica International's annual general meeting
2021BIOVICA INTERNATIONAL : DiviTum®TKa approaching FDA approval
2021BIOVICA INTERNATIONAL : CEO's presentation ahead of the 2021 Annual General Meeting has be..
2021TRANSCRIPT : Biovica International AB - Pre Recorded Shareholder/Analyst Call
2021BIOVICA INTERNATIONAL : strengthens management team
2021Biovica Appoints Warren Cresswell as President Americas
2021BIOVICA INTERNATIONAL : Notice of annual general meeting in Biovica International AB
2021BIOVICA INTERNATIONAL AB : – Annual report for the financial year 2020/2021 publishe..
2021TRANSCRIPT : Biovica International AB, Q4 2021 Earnings Call, Jun 18, 2021
2021BIOVICA INTERNATIONAL : Year-end Report February-April 2020/2021
2021Biovica International AB Publ Reports Earnings Results for the Fourth Quarter Ended Apr..
2021BIOVICA INTERNATIONAL : - Premium potential
2021TRANSCRIPT : Biovica International AB - Analyst/Investor Day
2021BIOVICA INTERNATIONAL : Capital Markets Day invitation June 9
2021BIOVICA INTERNATIONAL : DiviTumTKa shows strong capabilities in malignant melanoma
2021Biovica’S Divitumtka Shows Strong Capabilities in Malignant Melanoma
2021BIOVICA INTERNATIONAL : strengthens the management team
2021Biovica Announces Management Appointments
2021BIOVICA INTERNATIONAL : DiviTum®TKa budget impact model results show potential for savings..
2021TRANSCRIPT : Biovica International AB, Q3 2021 Earnings Call, Mar 18, 2021
2021BIOVICA INTERNATIONAL : Q3 Interim report November-January 2020/2021
2021BIOVICA INTERNATIONAL : DiviTumTKa prognostic for long-term outcome
2021Biovica International AB Publ Reports Earnings Results for the Third Quarter Ended Janu..
2021BIOVICA INTERNATIONAL : Nomination Committee for Biovica for the 2021 Annual General Meeti..
2021BIOVICA INTERNATIONAL : FDA resumes review of DiviTum®TKa submission
2021FDA Resumes Review of Biovica International's Divitum®TKA Submission
2021BIOVICA INTERNATIONAL : DiviTum®TKa in early treatment resistance trial
2021BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTum®TKa timeline
2021Biovica Announces FDA Resource Reallocation Continues to Impact DiviTum®TKa Timeline
2021BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of option pro..
2020TRANSCRIPT : Biovica International AB, Q2 2021 Earnings Call, Dec 08, 2020
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
2020Biovica International AB Reports Earnings Results for the Second Quarter Ended October ..
2020Certain Class B Shares of Biovica International AB are subject to a Lock-Up Agreement E..
2020BIOVICA INTERNATIONAL : DiviTum®TKa included in new UK breast cancer study
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTum®TKa results
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTum®TKa as an early and effectiv..
1  2  3Suiv.
Prochain événement sur BIOVICA INTERNATIONAL AB (PUBL)